• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Rao on dual PARP/AR inhibition in mCRPC


Arpit Rao, MD, an associate professor of Medical Oncology at Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the benefit of dual inhibition of the PARP and androgen receptor (AR) pathways in patients with prostate cancer. He also explains that a successful phase 2 trial (doi: 10.1016/S1470-2045(18)30365-6) of the AR pathway inhibitor (ARPI) abiraterone acetate (Zytiga) combined with the PARP inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC) inspired his colleagues and him to launch the CASPAR (Alliance A031902) trial, a randomized phase 3 trial of the ARPI enzalutamide (Xtandi) combined with the PARP inhibitor rucaparib (Rubraca) in patients with mCRPC (NCT04455750).

Related Videos
DNA helix | Image Credit: © Siarhei - stock.adobe.com
DNA strands | Image Credit: ©  Matthieu - stock.adobe.com
Keyan Salari, MD, PhD, answers a question during a Zoom video interview
Dr. Neal Shore in an interview with Urology Times
Related Content
© 2024 MJH Life Sciences

All rights reserved.